Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Chemotherapy Plus Radiation Therapy in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma

This study has been completed.
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: November 1, 1999
Last updated: May 8, 2010
Last verified: May 2010

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining radiation therapy with chemotherapy may kill more tumor cells. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy used to kill tumor cells.

PURPOSE: Phase II trial to study the effectiveness of chemotherapy plus radiation therapy in treating patients with refractory or relapsed Hodgkin's lymphoma.

Condition Intervention Phase
Biological: filgrastim
Drug: carboplatin
Drug: carmustine
Drug: cyclophosphamide
Drug: cytarabine
Drug: etoposide
Drug: ifosfamide
Drug: melphalan
Procedure: bone marrow ablation with stem cell support
Procedure: peripheral blood stem cell transplantation
Radiation: radiation therapy
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: High-Dose Chemo-Radiotherapy for Patients With Primary Refractory and Relapsed Hodgkin's Disease

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Estimated Enrollment: 80
Study Start Date: August 1998
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
  Show Detailed Description


Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Histologically confirmed residual or relapsed Hodgkin's lymphoma following conventional dose standard chemotherapy
  • Presence of the following prognostic factors are allowed:

    • B symptoms (fever, weight loss, night sweats)
    • Extranodal disease
    • Complete remission of less than 1 year duration



  • Not specified

Performance status:

  • Not specified

Life expectancy:

  • Not specified


  • Not specified


  • Bilirubin less than 2.0 mg/dL unless history of Gilbert's disease
  • No chronic active or persistent hepatitis


  • No history of chronic renal insufficiency
  • Creatinine no greater than 1.5 mg/dL OR
  • Creatinine clearance at least 60 mL/min


  • No myocardial infarction within the past 6 months
  • No unstable angina
  • No significant cardiac arrhythmias other than chronic atrial fibrillation
  • Ejection fraction at least 50%


  • DLCO at least 50%


  • No uncontrolled infection
  • HIV negative
  • At least 5 years since prior malignancy except:

    • Curatively treated cutaneous basal cell carcinoma
    • Carcinoma in situ of the cervix
  • Not pregnant or nursing
  • Fertile women must use effective contraception


  • Must have failed conventional dose standard chemotherapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00003631

United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10021
Sponsors and Collaborators
Memorial Sloan-Kettering Cancer Center
Study Chair: Joachim Yahalom, MD Memorial Sloan-Kettering Cancer Center
  More Information

Additional Information:
No publications provided Identifier: NCT00003631     History of Changes
Other Study ID Numbers: CDR0000066714, MSKCC-98071, NCI-G98-1480
Study First Received: November 1, 1999
Last Updated: May 8, 2010
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
recurrent adult Hodgkin lymphoma
recurrent/refractory childhood Hodgkin lymphoma

Additional relevant MeSH terms:
Hodgkin Disease
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms by Histologic Type
Alkylating Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antirheumatic Agents
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses processed this record on November 27, 2014